Matching articles for "Emend"
Issue 1614 · December 28, 2020
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

The FDA has approved IV amisulpride ( Barhemsys – Acacia), a selective dopamine-2 and -3 (D 2 /D 3 ) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults.…

Med Lett Drugs Ther. 2020 Dec 28; 62(1614):205-8
The FDA has approved IV amisulpride ( Barhemsys – Acacia), a selective dopamine-2 and -3 (D 2 /D 3 ) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Issue 1585 · November 18, 2019
Cannabis and Cannabinoids

Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of…

Med Lett Drugs Ther. 2019 Nov 18; 61(1585):179-82
Cannabis (marijuana) contains more than 60 pharmacologically active cannabinoids; delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known. THC is the main psychoactive constituent of cannabis. CBD, unlike THC, does not produce intoxication or euphoria.
Issue 1561 · December 3, 2018
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)

The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and…

Med Lett Drugs Ther. 2018 Dec 3; 60(1561):e200-1
The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Aprepitant is also available in oral capsule and suspension formulations ( Emend , and generics), and fosaprepitant, a prodrug of aprepitant, is available in an IV formulation ( Emend for injection).
Issue 1539 · January 29, 2018 Free
In Brief: Severe Hypersensitivity Reactions with Rolapitant IV Emulsion (Varubi)

The FDA has warned that the IV emulsion formulation of the substance P/neurokinin 1 (NK1) receptor antagonist rolapitant (Varubi) has been associated in postmarketing reports with serious hypersensitivity…

Med Lett Drugs Ther. 2018 Jan 29; 60(1539):24
The FDA has warned that the IV emulsion formulation of the substance P/neurokinin 1 (NK1) receptor antagonist rolapitant (Varubi) has been associated in postmarketing reports with serious hypersensitivity reactions including anaphylaxis and anaphylactic shock. 1 Rolapitant was approved by the FDA as an oral tablet in 2015 for adjunctive prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults 2 ; the IV emulsion formulation of the drug was approved for the same indication in 2017. The reported hypersensitivity reactions occurred during or shortly after infusion of rolapitant IV emulsion, and hospitalization was required in some cases. Rolapitant emulsion contains soybean oil; patients with known allergies to legumes or other related allergens may be at increased risk of developing a hypersensitivity reaction. IV fosaprepitant (Emend) , the other parenteral substance P/NK1 inhibitor formulation approved by the FDA, does not contain soybean oil, but has also been associated with serious hypersensitivity reactions. Patients with a history of hypersensitivity to soybean oil should not be treated with IV rolapitant. Those with known allergies to legumes or other related allergens should be monitored for signs of hypersensitivity during and following infusion of the emulsion. If a serious reaction occurs, use of rolapitant IV emulsion should be permanently discontinued. FDA. Varubi (rolapitant) injectable emulsion: health care provider letter – anaphylaxis and other serious hypersensitivity reactions. January 16, 2018. Available at: www.fda.gov. Accessed January 18, 2018. Rolapitant (Varubi) for prevention of delayed chemotherapy-induced nausea and vomiting. Med Lett Drugs Ther 2016; 58:17. Download complete U.S. English article
Issue 1500 · August 1, 2016
Cannabis and Cannabinoids

In the US, 25 states and the District of Columbia now permit some medical use of botanical marijuana (Cannabis sativa) . It has been used for centuries to treat various ailments, but non-standardization of…

Med Lett Drugs Ther. 2016 Aug 1; 58(1500):97-8
In the US, 25 states and the District of Columbia now permit some medical use of botanical marijuana (Cannabis sativa) . It has been used for centuries to treat various ailments, but non-standardization of dosage makes available data difficult to interpret. Cannabis contains >60 pharmacologically active cannabinoids.
Issue 1487 · February 1, 2016
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

The FDA has approved rolapitant ( Varubi – Tesaro), an oral substance P/neurokinin 1 (NK 1 ) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer…

Med Lett Drugs Ther. 2016 Feb 1; 58(1487):17-8
The FDA has approved rolapitant ( Varubi – Tesaro), an oral substance P/neurokinin 1 (NK 1 ) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK 1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT 3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
Issue 1467 · April 27, 2015
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting

The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist…

Med Lett Drugs Ther. 2015 Apr 27; 57(1467):61-3
The FDA has approved Akynzeo (Helsinn/Eisai), an oral fixed-dose combination of the substance P/neurokinin 1 (NK 1 ) receptor antagonist netupitant and the serotonin-3 (5-HT 3 ) receptor antagonist palonosetron, for prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy in adults. Akynzeo is the first product to combine drugs from these two classes. Palonosetron (Aloxi) is also available as a single agent for prevention of chemotherapy-induced and postoperative nausea and vomiting. Netupitant is the second substance P/NK 1 receptor antagonist to be approved in the US; aprepitant (Emend) was the first.
Issue 1337 · May 3, 2010
Everolimus and Pazopanib: Two New Drugs for Renal Cell Cancer

Everolimus ( Afinitor – Novartis) and pazopanib ( Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib…

Med Lett Drugs Ther. 2010 May 3; 52(1337):33-4
Everolimus ( Afinitor – Novartis) and pazopanib ( Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib (Sutent) and sorafenib (Nexavar) , two other oral multikinase inhibitors, and temsirolimus (Torisel) , an IV multikinase inhibitor, were approved earlier for the same indication.
Issue 1330 · January 25, 2010
Medical Marijuana

Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some…

Med Lett Drugs Ther. 2010 Jan 25; 52(1330):5-6
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa) . In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use.
Issue 1301 · December 15, 2008
A Granisetron Patch (Sancuso)

The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin…

Med Lett Drugs Ther. 2008 Dec 15; 50(1301):103-0
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation ( Sancuso - ProStrakan).
Issue 1297 · October 20, 2008
Drug Interactions with Simvastatin

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became…

Med Lett Drugs Ther. 2008 Oct 20; 50(1297):83-4
A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin ( Zocor , and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin ( Lipitor ) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.
Issue 1179 · March 29, 2004
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Palonosetron ( Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT 3 ) receptor antagonist to become available in the US and the first to be approved…

Med Lett Drugs Ther. 2004 Mar 29; 46(1179):27-8
Palonosetron ( Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT 3 ) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin ( Platinol , and others). Aprepitant ( Emend ), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT 3 antagonist and dexamethasone to prevent both acute and delayed nausea and vomiting due to highly emetogenic drugs ( Medical Letter 2003; 45:62 ).
Issue 1162 · August 4, 2003
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 )…

Med Lett Drugs Ther. 2003 Aug 4; 45(1162):62-3
Aprepitant ( Emend - Merck), the first substance P/neurokinin 1 (NK 1 ) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT 3 ) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.